Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Summary: Previous reports show increased incidence of venous thromboembolism [VTE, deep‐vein thrombosis (DVT) and pulmonary embolus (PE)] in sickle cell disease (SCD) patients but did not account for frequency of hospitalization. We determined the incidence of VTE in a SCD cohort versus matched controls. For SCD patients, risk factors for incident VTE, recurrence and the impact on mortality were also determined. Among 6237 patients with SCD, 696 patients (11·2%) developed incident‐VTE: 358 (51·6%) had PE (±DVT); 179 (25·7%) had lower‐extremity DVT only and 158 (22·7%) had upper‐extremity DVT. By 40 years of age, the cumulative incidence of VTE was 17·1% for severe SCD patients (hospitalized ≥3 times a year) versus 8·0% for the matched asthma controls. Amongst SCD patients, women (Hazard ratio [HR] = 1·22; 95% confidence interval [CI]: 1·05–1·43) and those with severe disease (HR = 2·86; 95% CI: 2·42–3·37) had an increased risk of VTE. Five‐year recurrence was 36·8% in patients with severe SCD. VTE was associated with increased risk of death (HR = 2·88, 95% CI: 2·35–3·52). In this population‐based study, the incidence of VTE was higher in SCD patients than matched controls and was associated with increased mortality. The high incidence of recurrent VTE in patients with severe SCD suggests that extended anticoagulation may be indicated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340
Pain in Sickle Cell Disease: Rates and Risk Factors
Platt, O. S., Thorington, B. D., Brambilla, D. J., Milner, P. F., Rosse, W. F., Vichinsky, E., & Kinney, T. R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107043250103 · Cited by 1,546 · cited 1×
“SCD severity classification was based on previously published data showing greater mortality in SCD patients with ≥3 hospitalizations per year (Platt et al, 1991), and criterion that was later used as one of the indications for starting hydroxycarbamide (also termed hydroxyurea) treatment in the…”
MethodKearon, C., Ageno, W., Cannegieter, S. C., Cosmi, B., Geersing, G. ‐., & Kyrle, P. A. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13336 · Cited by 587
Cited by
Increased risk of leukemia among sickle cell disease patients in California
Brunson, A., Keegan, T. H. M., Bang, H., Mahajan, A., Paulukonis, S., & Wun, T. (2017) · Blood · doi:10.1182/blood-2017-05-783233 · Cited by 139
Self-citationHerring, W. L., Gallagher, M. E., Shah, N., Morse, K., Mladsi, D., Dong, O. M., Chawla, A., Leiding, J. W., Zhang, L., Paramore, C., et al. (2024) · PharmacoEconomics · doi:10.1007/s40273-024-01385-9 · Cited by 18
Trained Immunity Causes Myeloid Cell Hypercoagulability
Rehill, A. M., McCluskey, S., Ledwith, A. E., Ryan, T. A. J., Ünlü, B., Leon, G., Charles-Messance, H., Gilbert, E. H., Klavina, P., Day, E. A., et al. (2025) · Science Advances · doi:10.1126/sciadv.ads0105 · Cited by 12
Metadata
- Authors
- Brunson, A., Lei, A., Rosenberg, A. S., White, R. H., Keegan, T., & Wun, T.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2017-04-03
- Volume
- 178
- Issue
- 2
- Pages
- 319-326
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2605277819
- Cited by
- 129
- References
- 3
- FWCI
- 5.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.